Switch theme
Sign up to access all valuation multiples
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
1995
103
LTM Revenue $20.1M
LTM EBITDA -$165M
$134M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lexicon Pharmaceuticals has a last 12-month revenue (LTM) of $20.1M and a last 12-month EBITDA of -$165M.
In the most recent fiscal year, Lexicon Pharmaceuticals achieved revenue of $31.1M and an EBITDA of -$184M.
Lexicon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lexicon Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $20.1M | XXX | $31.1M | XXX | XXX | XXX |
| Gross Profit | $19.6M | XXX | $30.5M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | -$165M | XXX | -$184M | XXX | XXX | XXX |
| EBITDA Margin | -819% | XXX | -593% | XXX | XXX | XXX |
| EBIT | -$165M | XXX | -$197M | XXX | XXX | XXX |
| EBIT Margin | -821% | XXX | -634% | XXX | XXX | XXX |
| Net Profit | -$167M | XXX | -$200M | XXX | XXX | XXX |
| Net Margin | -832% | XXX | -645% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $33.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lexicon Pharmaceuticals's stock price is $1.
Lexicon Pharmaceuticals has current market cap of $227M, and EV of $134M.
See Lexicon Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $134M | $227M | XXX | XXX | XXX | XXX | $-0.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lexicon Pharmaceuticals has market cap of $227M and EV of $134M.
Lexicon Pharmaceuticals's trades at 4.3x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Lexicon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lexicon Pharmaceuticals has a P/E ratio of -1.4x.
See valuation multiples for Lexicon Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $227M | XXX | $227M | XXX | XXX | XXX |
| EV (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -0.8x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLexicon Pharmaceuticals's last 12 month revenue growth is -58%
Lexicon Pharmaceuticals's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $2.2M for the same period.
Lexicon Pharmaceuticals's rule of 40 is -13635% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lexicon Pharmaceuticals's rule of X is -964% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lexicon Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -58% | XXX | -33% | XXX | XXX | XXX |
| EBITDA Margin | -819% | XXX | -593% | XXX | XXX | XXX |
| EBITDA Growth | -26% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -13635% | XXX | -651% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -964% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 272% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 732% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lexicon Pharmaceuticals acquired XXX companies to date.
Last acquisition by Lexicon Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Lexicon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lexicon Pharmaceuticals founded? | Lexicon Pharmaceuticals was founded in 1995. |
| Where is Lexicon Pharmaceuticals headquartered? | Lexicon Pharmaceuticals is headquartered in United States of America. |
| How many employees does Lexicon Pharmaceuticals have? | As of today, Lexicon Pharmaceuticals has 103 employees. |
| Who is the CEO of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's CEO is Dr. Michael Exton, PhD. |
| Is Lexicon Pharmaceuticals publicy listed? | Yes, Lexicon Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals trades under LXRX ticker. |
| When did Lexicon Pharmaceuticals go public? | Lexicon Pharmaceuticals went public in 2000. |
| Who are competitors of Lexicon Pharmaceuticals? | Similar companies to Lexicon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's current market cap is $227M |
| What is the current revenue of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's last 12 months revenue is $20.1M. |
| What is the current revenue growth of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals revenue growth (NTM/LTM) is -58%. |
| What is the current EV/Revenue multiple of Lexicon Pharmaceuticals? | Current revenue multiple of Lexicon Pharmaceuticals is 6.7x. |
| Is Lexicon Pharmaceuticals profitable? | Yes, Lexicon Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's last 12 months EBITDA is -$165M. |
| What is Lexicon Pharmaceuticals's EBITDA margin? | Lexicon Pharmaceuticals's last 12 months EBITDA margin is -819%. |
| What is the current EV/EBITDA multiple of Lexicon Pharmaceuticals? | Current EBITDA multiple of Lexicon Pharmaceuticals is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
